Related Experiment Video
Updated: Mar 6, 2026
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
5.3K
Nepalese patients' anti-diabetic medication taking behaviour: an exploratory study
Sujata Sapkota1, Jo-Anne E Brien1,2, Parisa Aslani1
1a Faculty of Pharmacy , The University of Sydney , Sydney , Australia.
Ethnicity & Health
|March 10, 2017
Summary
Nepalese patients with type 2 diabetes often delay or stop anti-diabetic medications due to reluctance and misunderstanding. Education and addressing psychological barriers are key for effective medication adherence.
Area of Science:
- Endocrinology
- Behavioral Science
- Public Health
Background:
- Type 2 diabetes management requires consistent anti-diabetic medication adherence.
- Understanding medication-taking behaviors in diverse patient populations is crucial for effective treatment.
Purpose of the Study:
- To explore anti-diabetic medication-taking behaviors in Nepalese patients with type 2 diabetes.
- To identify factors influencing medication adherence in this specific demographic.
Main Methods:
- Qualitative face-to-face interviews with 48 Nepalese patients in Australia and Nepal.
- Thematic analysis of transcribed interviews.
- Quantitative assessment of medication adherence using the Summary of Diabetes Self-Care Activity (SDSCA) questionnaire.
Main Results:
- Medication-taking behavior often followed the Stages of Change Model, with most initiating medications promptly.
- Delayed initiation or cessation occurred due to reluctance, preference for natural treatments, and inadequate understanding.
- High self-reported adherence (97.3%) was observed, with daily challenges related to forgetfulness and meal inconsistencies.
- Doctor's encouragement and increased disease awareness positively impacted adherence.
Conclusions:
- Nepalese patients may delay or cease anti-diabetic medications until fully accepting their necessity.
- Patient education on the importance of medication is vital.
- Strategies to address psychological resistance to medication are essential for effective diabetes management.
Related Concept Videos
01:28Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
331
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
762
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
762
01:06Oral Hypoglycemic Agents: Glinides
780
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
780
01:21Drug Dosing: Obese Patients
320
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320